On April 18, Hirokazu Matsugami, Director and Vice President of Sumitomo Pharma, led a core management team to visit Chi Heal Bio (Shandong) Pharmaceutical Co., Ltd. for in-depth discussions on the Lefamulin Acetate project, accompanied by leaders from Heze Medical Port. Hou Junqi, General Manager of Chi Heal Bio (Shandong) Pharmaceutical, warmly received the delegation. The two parties reached key agreements on CMO/CDMO outsourcing and implementation, marking a substantive step forward in their collaboration.

As an emerging enterprise specializing in CMO/CDMO, Chi Heal Bio (Shandong) Pharmaceutical has established a full-chain service system covering R&D, production, and sales, supported by a 100-acre modern industrial base. Equipped with intelligent production lines meeting international standards and a professional R&D team, the company has successfully provided customized services—from process development to large-scale production—for multiple domestic and international pharmaceutical companies, accumulating deep expertise in advanced complex formulation technologies. During the talks, Chi Heal Bio earned high praise from Sumitomo Pharma for its proven experience and efficient production capacity. Both sides engaged in pragmatic discussions on core outsourcing aspects of the Lefamulin Acetate project, including registration batch production, quality control, and mass production scheduling, ultimately defining a clear cooperation roadmap.

Leaders from Heze Medical Port expressed strong expectations for the collaboration, noting that this not only represents a major breakthrough for Chi Heal Bio (Shandong) Pharmaceutical in the global CMO/CDMO arena but will also inject strong momentum into the development of the regional pharmaceutical industry cluster. Hou Junqi, General Manager of Chi Heal Bio (Shandong) Pharmaceutical, stated that the company will leverage this opportunity to fully utilize its technical and service strengths in formulation R&D and production, strictly adhere to international quality standards, and efficiently advance the Lefamulin Acetate project. By providing full-cycle, high-quality services to Sumitomo Pharma, Chi Heal Bio aims to accelerate access to high-quality medicines for domestic patients while continuously enhancing the global competitiveness of China’s pharmaceutical CDMO sector.